Registered Nurse in Merriam, KS Accepting Medicare
9 Registered Nurse nurses found. Showing 1 - 9
 Megan Patricia Beemer, CNM Registered Nurse - Maternal Newborn Medicare: Accepting Medicare Assignments Practice Location: 9100 W 74th St, Merriam, KS 66204 Phone: 913-676-2433 Fax: 913-789-6700 |
Ms. Kristen Mulholland, R.N. Registered Nurse - Orthopedic Medicare: Not Enrolled in Medicare Practice Location: 8812 W 72nd St, Merriam, KS 66204 Phone: 913-634-2116 |
Andrea Nicole Macy-sturgis, APRN Registered Nurse - Pediatric Oncology Medicare: Accepting Medicare Assignments Practice Location: 6815 Frontage Rd, Merriam, KS 66204 Phone: 816-478-4200 |
Holland Hayes, BSN, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 9925 W 67th St, Merriam, KS 66203 Phone: 913-206-5234 |
Angela Cronister, RN Registered Nurse - Emergency Medicare: Not Enrolled in Medicare Practice Location: 9100 W 74th St, Merriam, KS 66204 Phone: 913-676-2218 |
Jordan Alexandra Cunningham, APRN Registered Nurse - Oncology Medicare: Medicare Enrolled Practice Location: 9301 W 74th St Ste 100, Merriam, KS 66204 Phone: 913-632-9100 |
 Peter Evanciew Iii, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 6700 Antioch Road, Suite 430, Merriam, KS 66204 Phone: 888-652-9225 |
Mrs. Valerie Njuguna, NP-C Registered Nurse - Gerontology Medicare: May Accept Medicare Assignments Practice Location: 9700 W 62nd St, Merriam, KS 66203 Phone: 913-384-0800 |
Brianna Cole, Registered Nurse - Emergency Medicare: Not Enrolled in Medicare Practice Location: 9100 W 74th St, Merriam, KS 66204 Phone: 913-676-2000 |
News Archive
Value of Colorectal Cancer therapeutics market expected to increase $9.4 billion by 2020
Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.
FDA grants orphan drug status to Advanced Life Sciences' Restanza
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.
UK measles cases at relatively low levels
So far this year, numbers of measles cases are still at relatively low levels; there were 150 confirmed cases in the first half of 2004 compared with 296 cases in the same period in 2003.
Lobbying groups prepare for reconciliation process, step up fight on bill features
Lobbyists are beginning to consider how their clients would fare if health reform moves to a reconciliation process to pass legislation, Roll Call reports.
› Verified 4 days ago